Please ensure Javascript is enabled for purposes of website accessibility
Taylor Carmichael

Taylor Carmichael


Taylor Carmichael is a former attorney and filmmaker. He's the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.

Recent articles


Nano-X Imaging Receives FDA Clearance for X-Ray Device

The company will start shipping its X-ray machines to hospitals in the fourth quarter of 2021.


2 Biotech Stocks That Could Be Millionaire Makers

Why OptimizeRx and Ontrak might make you rich.

female pharmacist holds a bottle of medication

2 Great Stocks Under $10 per Share

Amarin and Accelerate Diagnostics are healthcare companies with significant upside.

GettyImages-539282157 (1)

Is Chuy's Stock a Buy?

This restaurant stock is up 47% in 2021 and up an amazing 270% from a year ago. Why is Chuy's stock doing so well, and will it continue?


Cathie Wood Owns Schrodinger Stock: Should You?

Wood's biotech fund owns almost $200 million worth of Schrodinger, about 2% of the company. Here's why she's an investor.


If I Had $5,000, This Is How I'd Invest It

I'd increase my stakes in two small caps that I already own.


SPACs: Why Are They On Fire Right Now?

More and more tech companies are avoiding the IPO and using a SPAC to come public. What's going on?


Biotech Stocks: What Will 2021 Look Like?

2020 was a wild run for the biotech sector, with COVID-19 dominating the headlines. What will happen this year?


3 Unstoppable Healthcare Stocks to Buy on the Dip

Intuitive Surgical, Teladoc Health, and Veeva Systems all have fantastic opportunities and should make investors a lot of money over the next decade.


2 Hot SPACs Investors Should Watch

23andMe and Butterfly Networks are two private biotech companies hitting the public markets soon.


Why You Should Own Biotech Stocks Now

The confluence of healthcare and technology will send many biotech stocks soaring over the next decade.


What Are the Risks of Investing in Biotech Stocks?

The sector has incredible upside over the next decade. How should investors approach this market opportunity?


1 Green Flag for Axsome Therapeutics

The upstart biotech is filing two new drug applications in 2021, and has several more on the way.


What Are Novavax's Long-Term Prospects?

It's shifting from an unprofitable biotech to a company collecting billions in revenue.


Is Nano-X a Buy?

This healthcare disrupter is about to receive FDA clearance to start distributing its new X-ray device.

4 SPACs for the Future

A rocket company, a 3-D capture software company, and two biotechs are about to hit the public markets. Smart investors can get in now via special purpose acquisition companies.


Nano-X Imaging: Buy the Dip?

The X-ray disrupter is almost 50% off its highs.


1 Under-the-Radar Stock For Healthcare Investors to Buy Now

OptimizeRx is disrupting the pharmaceutical sales call with an internet option for marketing drugs to doctors.


What's the Strongest Buy: Moderna, Teladoc Health, or Fulgent Genetics?

All three of these stocks have had incredible spikes because of COVID-19. One stock, however, is a safer and stronger long-term investment.


1 Green Flag for Fulgent Genetics

Here's why Fulgent stock is running so high.